16th July 2012 - News release

NEUPRO LAUNCHED IN THE U.S.A. TO TREAT PARKINSON'S DISEASE

The role of UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome. Neupro is a once-daily patch that provides continuous delivery of the dopamine agonist rotigotine for 24 hours. Neupro is available in four different dosage strengths for the signs and symptoms of Parkinson’s disease (2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours, and 8 mg/24 hours).

In clinical trials, the most common adverse reactions were nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, insomnia, hyperhidrosis, peripheral edema, and dyskinesia. There is an increased risk for hallucinations in people with advanced-stage Parkinson’s Disease when they are treated with Neupro. Neupro may cause symptomatic postural/orthostatic hypotension and syncope (fainting), especially during dose escalation, elevated blood pressure, elevated heart rate, weight gain and fluid retention. Neupro should be used with caution in people with severe cardiovascular disease.